Nils Feltelius

SARS-CoV-2 vaccination and myositis in Norway and Sweden

Ljung, Rickard; Pihlström, Nicklas; Dahl, Jesper; Tapia, German et al.

Ingår i Rheumatology, 2026

• DOI för SARS-CoV-2 vaccination and myositis in Norway and Sweden
• Ladda ner fulltext (pdf) av SARS-CoV-2 vaccination and myositis in Norway and Sweden

A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence

Melinder, Maria; Windfuhr, Fabian; Dahlqvist, Tanja; Torre, Carla et al.

Ingår i Pharmacoepidemiology and Drug Safety, 2026

• DOI för A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence
• Ladda ner fulltext (pdf) av A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence

Non-steroidal anti-inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high-use populations

Wadstrom, Hjalmar; Askling, Johan; Gedeborg, Rolf; Feltelius, Nils et al.

Ingår i Journal of Internal Medicine, s. 505-517, 2025

• DOI för Non-steroidal anti-inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high-use populations
• Ladda ner fulltext (pdf) av Non-steroidal anti-inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high-use populations

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Frisell, Thomas; Bower, Hannah; Morin, Matilda; Baecklund, Eva et al.

Ingår i Annals of the Rheumatic Diseases, s. 601-610, 2023

• DOI för Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
• Ladda ner fulltext (pdf) av Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Federated analyses of multiple data sources in drug safety studies

Gedeborg, Rolf; Igl, Wilmar; Svennblad, Bodil; Wilén, Peter et al.

Ingår i Pharmacoepidemiology and Drug Safety, s. 279-286, 2023

• DOI för Federated analyses of multiple data sources in drug safety studies
• Ladda ner fulltext (pdf) av Federated analyses of multiple data sources in drug safety studies

SARS-CoV-2 vaccination and myositis in Norway and Sweden

Ljung, Rickard; Pihlström, Nicklas; Dahl, Jesper; Tapia, German et al.

Ingår i Rheumatology, 2026

• DOI för SARS-CoV-2 vaccination and myositis in Norway and Sweden
• Ladda ner fulltext (pdf) av SARS-CoV-2 vaccination and myositis in Norway and Sweden

A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence

Melinder, Maria; Windfuhr, Fabian; Dahlqvist, Tanja; Torre, Carla et al.

Ingår i Pharmacoepidemiology and Drug Safety, 2026

• DOI för A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence
• Ladda ner fulltext (pdf) av A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence

Non-steroidal anti-inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high-use populations

Wadstrom, Hjalmar; Askling, Johan; Gedeborg, Rolf; Feltelius, Nils et al.

Ingår i Journal of Internal Medicine, s. 505-517, 2025

• DOI för Non-steroidal anti-inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high-use populations
• Ladda ner fulltext (pdf) av Non-steroidal anti-inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high-use populations

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Frisell, Thomas; Bower, Hannah; Morin, Matilda; Baecklund, Eva et al.

Ingår i Annals of the Rheumatic Diseases, s. 601-610, 2023

• DOI för Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
• Ladda ner fulltext (pdf) av Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision

Bower, Hannah; Frisell, Thomas; di Giuseppe, Daniela; Delcoigne, Bénédicte et al.

Ingår i RMD Open, 2021

• DOI för Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision
• Ladda ner fulltext (pdf) av Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

Askling, J; Fored, C M; Brandt, L; Baecklund, Eva et al.

Ingår i Annals of the Rheumatic Diseases, s. 1421-1426, 2005

• DOI för Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

Federated analyses of multiple data sources in drug safety studies

Gedeborg, Rolf; Igl, Wilmar; Svennblad, Bodil; Wilén, Peter et al.

Ingår i Pharmacoepidemiology and Drug Safety, s. 279-286, 2023

• DOI för Federated analyses of multiple data sources in drug safety studies
• Ladda ner fulltext (pdf) av Federated analyses of multiple data sources in drug safety studies

Från romerska bad till hälsobrunnar och rehabiliteringsträdgårdar: Medicinhistoriska perspektiv på begreppet "Grön hälsa"

Feltelius, Nils

Ingår i Uppsala Medicinhistoriska Förenings Årsskrift 2022, s. 86-105, Uppsala Medicinhistoriska Förening, 2022